Page last updated: 2024-10-23

azelastine and Disease Exacerbation

azelastine has been researched along with Disease Exacerbation in 3 studies

azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Meltzer, E2
Ratner, P1
Bachert, C2
Carr, W2
Berger, W2
Canonica, GW1
Hadley, J1
Lieberman, P2
Hampel, FC1
Mullol, J1
Munzel, U2
Price, D2
Scadding, G1
Virchow, JC1
Wahn, U1
Murray, R1
Bousquet, J3
Meltzer, EO1
Amar, N1
Fox, AT1
Just, J1
Muraro, A1
Nieto, A1
Valovirta, E1
Wickman, M1
Bernstein, J1

Trials

3 trials available for azelastine and Disease Exacerbation

ArticleYear
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
    International archives of allergy and immunology, 2013, Volume: 161, Issue:4

    Topics: Adult; Androstadienes; Anti-Allergic Agents; Cedrus; Disease Progression; Drug Combinations; Female;

2013
Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2016, Volume: 27, Issue:2

    Topics: Caregivers; Child; Child, Preschool; Disease Progression; Drug Combinations; Female; Fluticasone; Hu

2016
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    The Journal of allergy and clinical immunology, 2012, Volume: 129, Issue:5

    Topics: Administration, Intranasal; Adult; Androstadienes; Disease Progression; Drug Combinations; Female; F

2012